Intas Biopharmaceuticals

The Biologics Business Unit (BU) of Intas Pharmaceuticals Limited was formerly an independent biotechnology company and was known as Intas Biopharmaceuticals Ltd. Intas Pharmaceuticals limited is an Indian company headquartered in Ahmedabad, India. The Biologics BU is located in Moraiya, Ahmedabad and is one of the leading biosimilar product manufacturers in Asia.
The Biologics BU of Intas Pharmaceuticals has biopharmaceutical operations with R&D facility and an EU-GMP certified bio-pharmaceutical manufacturing facility.
History.
Intas Biopharmaceuticals Limited was set up in 1980 by Dr Urmish Chudgar, a leading hematooncologist, as an independent biotechnology division of Intas Pharmaceuticals Ltd. It is a mid-sized generic formulation manufacturer located in Ahmedabad, India. The division was merged with the parent company Intas Pharmaceuticals Limited in 2013. Now, Intas Biopharmaceuticals is headed by Mr. Hasmukh Chudgar.
The company faced an EU-GMP (Good Manufacturing Practice) audit in December 2006, to seek approval for a clinical trial of its biosimilar Filgrastim in Europe and was certified as EU-GMP compliant in April 2007, becoming the first company in India to receive such certification.
Apart from EU-GMP certification, the company has approvals from MCC South Africa, Gulf Cooperation Council (GCC), Syria, Yemen, Belarus and several other national health authorities for its manufacturing facility and products.
In 2015, the company launched Accofil, a treatment for immune system disorders. In 2016, Intas acquired the assets of Teva Pharmaceuticals in the UK and Ireland for $764 million.
In 2017, the company announced acquisition of Actavis UK Ltd. & Actavis Ireland Ltd from Teva Pharmaceutical Industries Ltd, for an enterprise value of GBP 603 million.